• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, September 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Subtype of immune B cells can delay type 1 diabetes onset in mice

Bioengineer by Bioengineer
December 6, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Baylor College of Medicine


A team of researchers at Baylor College of Medicine and the University of Michigan Medical School reports today in the JCI Insight that a subset of immune B cells, known as CD19+IgM+ B cells, can delay the onset of type 1 diabetes in a mouse model of the condition. These findings open an opportunity to develop novel treatments for a subgroup of diabetes mellitus that affects about 420 million people around the world.

“For many years, one of the research interests of my lab has been to better understand the role the immune system plays in type 1 diabetes,” said corresponding author Dr. Massimo Pietropaolo, professor of medicine-endocrinology and McNair scholar at Baylor College of Medicine.

Increasing experimental evidence supports an important role of B cells, a subset of immune cells, in the development of diabetes, both in animal models and in humans. It’s been shown, for example, that subsets of B cells can directly contribute to disease development.

“However, there are also indications that subsets of B cells may be involved in modulating the onset of the condition,” Pietropaolo explains. “For instance, elimination of a specific subset of B cells carrying the μ-chain marker resulted in impaired diabetes progression in a mouse model.”

In this study, Pietropaolo and his colleagues studied in more detail a specific subset of B cells, called CD19+ IgM+ B cells and how they affected the onset of diabetes in a mouse model of the condition.

The researchers discovered that when they transferred CD19+ IgM+ B cells to the mice, they were able to delay diabetes onset. The protective effect seems to be age specific. CD19+ IgM+ B cells from 6-week-old mice delayed diabetes onset, unlike CD19+ IgM+ B cells from mice older than 15 weeks.

“We are the firsts to describe that CD19+ IgM+ B cells play a strong regulatory effect that delays diabetes onset in a mouse model,” Pietropaolo said. “Taken together, our results open the future possibility of developing new therapies for this disease by expanding this specific B cell subtype pharmacologically and in turn modulating their regulatory actions in ways that would interfere with the onset of type 1 diabetes.”

###

Other author of this work include Andrew D. Vonberg, María Acevedo-Calado, Aaron R. Cox, Susan L. Pietropaolo and Roberto Gianani, all from Baylor, and Steven K. Lundy from the University of Michigan Medical School.

This work was supported by McNair Medical Institute at The Robert and Janice McNair Foundation, NIH T32 Training grant (T32AI007413) and the Michigan Diabetes Research Training Center (MDRTC) funded by NIH grant 5P60-DK020572.

Media Contact
Julia Bernstein
[email protected]
713-798-4710

Related Journal Article

http://dx.doi.org/10.1172/jci.insight.99860

News source: https://scienmag.com/

Tags: BiologyDiabetesEndocrinologyImmunology/Allergies/AsthmaMetabolism/Metabolic DiseasesPhysiology
Share12Tweet8Share2ShareShareShare2

Related Posts

Exploring Glioma Stem Cell Variations and Treatments

September 3, 2025

Impact of Unsafe Uterotonics on Health and Economy

September 3, 2025

New Ashwagandha Formula Shows Enhanced Bioavailability in Study

September 3, 2025

Link Between Binge Eating Disorder and Self-Harm Revealed

September 3, 2025
Please login to join discussion

POPULAR NEWS

  • Needlestick Injury Rates in Nurses and Students in Pakistan

    297 shares
    Share 119 Tweet 74
  • Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    155 shares
    Share 62 Tweet 39
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    143 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    118 shares
    Share 47 Tweet 30

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Transformers Enhance Sentiment Analysis in Chinese Education

Assessing Climate Impact of Green Biorefineries in Denmark

Microbiome Traits Boost Plant Growth, Sustain Agriculture

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.